High-RS patients exhibited worse OS, higher tumorigenic events, lower gene mutation rates, and decreased sensitivity to anti-PD-L1 treatment; analysis in pan-cancer cell lines revealed that the RS was associated with IC50s of 41 anti-tumor drugs. This evidence concerns the gene CD274 and neoplasm.